|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM330510967 |
| 003 |
DE-627 |
| 005 |
20250302114324.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108851
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1101.xml
|
| 035 |
|
|
|a (DE-627)NLM330510967
|
| 035 |
|
|
|a (NLM)34508889
|
| 035 |
|
|
|a (PII)S1521-6616(21)00188-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hetemäki, Iivo
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Patients with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe herpesvirus infections
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.10.2021
|
| 500 |
|
|
|a Date Revised 21.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Almost all patients with autoimmune polyendocrine syndrome type 1 (APS-1) have neutralizing antibodies against type 1 interferons (IFN), important mediators of antiviral defense. Recently, neutralizing anti-IFN antibodies were shown to be a risk factor of severe COVID-19. Here we show in a cohort of 44 patients with APS-1 that higher titers of neutralizing anti-IFNα4 antibodies are associated with a higher and earlier incidence of VZV reactivation (herpes zoster). The patients also present with uncommonly severe clinical sequelae of herpetic infections. APS-1 patients had decreased humoral immune responses to varicella zoster virus, but cellular responses were comparable to healthy controls. These results suggest that blocking the type I interferon pathway in patients with APS-1 patients leads to a clinically significant immune deficiency, and susceptibility to herpesviruses should be taken into account when treating patients with APS-1
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a AIRE
|
| 650 |
|
4 |
|a Autoantibody
|
| 650 |
|
4 |
|a Herpes simplex
|
| 650 |
|
4 |
|a Herpes zoster
|
| 650 |
|
4 |
|a Immunodeficiency
|
| 650 |
|
4 |
|a Type I interferon
|
| 650 |
|
4 |
|a Varicella zoster
|
| 650 |
|
7 |
|a Interferon-alpha
|2 NLM
|
| 700 |
1 |
|
|a Laakso, Saila
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Välimaa, Hannamari
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kleino, Iivari
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kekäläinen, Eliisa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mäkitie, Outi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arstila, T Petteri
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 231(2021) vom: 01. Okt., Seite 108851
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:231
|g year:2021
|g day:01
|g month:10
|g pages:108851
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108851
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 231
|j 2021
|b 01
|c 10
|h 108851
|